<DOC>
	<DOCNO>NCT00258206</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together cyclophosphamide may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together cyclophosphamide work treat patient high risk , refractory , relapse multiple myeloma .</brief_summary>
	<brief_title>Rituximab Cyclophosphamide Treating Patients With High Risk , Refractory , Relapsed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect rituximab high-dose cyclophosphamide growth myeloma stem cell patient high-risk , refractory , relapse multiple myeloma . OUTLINE : Patients receive rituximab IV day -10 -7 ; weekly 4 week ( completion high-dose cyclophosphamide ) ; month 3 , 6 , 9 , 12 . Patients also receive high-dose cyclophosphamide day -3 0 . PROJECTED ACCRUAL : Not specify .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma , meet 1 follow criterion : Highrisk disease first remission , define follow : Beta2 microglobulin &gt; 5.0 mg/dL Chromosome 13 deletion Primary refractory disease Relapsed disease achieve response prior chemotherapy The following diagnosis allow : POEMS syndrome Plasma cell leukemia Amyloidosis Nonsecretory myeloma No evidence spinal cord compression PATIENT CHARACTERISTICS : Age Over 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Fertile patient must use effective contraception HIV negative Has good organ function Is good physical condition No active infection require antibiotic No malignancy within past 2 year except basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No persistently detectable donor cell prior allogeneic stem cell transplantation No prior rituximab Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 28 day since prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>